Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)1

Siragusa, Sergio; Armani, U; Carpenedo, Monica; Falanga, Anna; Fulfaro, Fabio; Imberti, Davide; Laurora, Renzo; Molinari, Angelo Claudio; Prisco, Domenico; Silingardi, Mauro; Verso, Melina; Visonà, Adriana

doi:10.1016/j.thromres.2011.09.002

Cited by 43 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous national and international guidelines, 28,[78][79][80][81][82][83][84][85][86]95 some cancer specific, 79,81,[83][84][85] have been produced in an effort to improve TP practice and over time have become more detailed and comprehensive. Although cross-sectional international surveys have demonstrated compliance rates of <60%, 96 ambulatory patients with advanced GI cancer having CT (AIOM 2010) or patients with "lung or GI cancer" and those with a previous history of TE (SISET 2011).…”

Section: Examining Tp Guidelinesmentioning

confidence: 99%

Thromboembolism During Neoadjuvant Therapy for Gastrointestinal Cancer

Smart

Burbury²,

Lynch³

et al. 2014

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Thromboembolism a common, costly, and morbid complication that is also associated with decreased survival in cancer patients. The risk of thromboembolism in cancer patients is underappreciated. In addition to symptomatic deep venous thrombosis and pulmonary embolism, asymptomatic and arterial thromboembolic events are important consideration in ambulatory cancer patients receiving neoadjuvant chemoradiotherapy (nCRT). No specific randomized trial examining thromboprophylaxis (TP) during nCRT for gastrointestinal cancer has been performed, and none is accruing. Most guidelines currently recommend against TP in ambulatory cancer patients due to a lack of data rather than proof of harm or lack of efficacy. It is clear that robust data are urgently required, and that treatment with nCRT in patients with gastrointestinal malignancy is not an indication for routine pharmacological TP at the present time.

show abstract

Section: Examining Tp Guidelinesmentioning

confidence: 99%

Thromboembolism During Neoadjuvant Therapy for Gastrointestinal Cancer

Smart

Burbury²,

Lynch³

et al. 2014

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Guidelines of the American Society of Clinical Oncology, European Society of Medical Oncology, and Italian Society for Haemostasis and Thrombosis recommend prophylaxis with LMWH or adjusteddose warfarin [international normalized ratio (INR) 2-3] [56][57][58]. The International Myeloma Working Group proposes different thromboprophylactic strategies based on stratification of the patient's risk of VTE [59].…”

Section: Prophylaxis Of Venous Thromboembolismmentioning

confidence: 99%

Venous thromboembolism in the hematologic malignancies

Falanga

Marchetti

Russo

2012

Current Opinion in Oncology

Self Cite

View full text Add to dashboard Cite

Thrombotic complications have a significant impact on morbidity and mortality of hematological cancer patients, therefore, in this setting, the issue of thromboprophylaxis to prevent VTE is important. However, no clear recommendation in these conditions is available, with the exception of multiple myeloma. Large prospective randomized clinical trials are needed to establish the best practice for prevention and treatment of VTE in these types of malignant diseases.

show abstract

“…A number of international and national guidelines outlining optimal TP practice have been produced, including some that are cancer‐specific . However, most TP guidelines currently acknowledge a lack of data in the setting of nCRT, TP and extended post‐operative phases and offer only general recommendations for consideration of TP in high‐risk patients.…”

Section: Introductionmentioning

confidence: 99%